Expanding the roster: Developing new inhibitors of intravascular thrombosis

Journal of the American College of Cardiology

Volumn 65, Issue 22, 2015, Pages 2416-2419

  Kleiman, Neal S ^a,b   Kolandaivelu, Kumaran ^c,d,e  

^a HOUSTON METHODIST RESEARCH INSTITUTE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d HARVARD MEDICAL SCHOOL   (United States)

^e MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

antithrombotic; glycoprotein; plaque homogenate

Indexed keywords

ANTICOAGULANT AGENT; CANGRELOR; GLYCOPROTEIN VI INHIBITOR; HEMATOLOGIC AGENT; PRASUGREL; RIVAROXABAN; TICAGRELOR; UNCLASSIFIED DRUG; VORAPAXAR;

ATHEROSCLEROSIS; BLEEDING; CEREBROVASCULAR ACCIDENT; DRUG BINDING; DRUG INDICATION; DRUG SAFETY; DRUG TARGETING; DRUG TOLERANCE; HUMAN; MEDICAL DECISION MAKING; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NONHUMAN; NOTE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SECONDARY PREVENTION; THROMBOCYTE AGGREGATION; THROMBOSIS; DRUG DEVELOPMENT; PROCEDURES;

ANTICOAGULANTS; DRUG DISCOVERY; HUMANS; THROMBOSIS;

EID: 84930895799     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2015.03.576     Document Type: Editorial

References (15)

1. D.S. Menees, E.D. Peterson, and Y. Wang Door-to-balloon time and mortality among patients undergoing primary PCI N Engl J Med 369 2013 901 909
2. Cannon C. IMPROVE-IT trial: a comparison of ezetimibe/simvastatin versus simvastatin monotherapy on cardiovascular outcomes after acute coronary syndromes. Presented at: Annual Scientific Sessions of the American Heart Association; November 17, 2014; Chicago, IL.
3. S.S. Jolly, J.A. Cairns, S. Yusuf for the TOTAL Investigators Randomized trial of primary PCI with or without routine manual thrombectomy N Engl J Med 372 2015 1389 1398
4. M.P. Bonaca, D.L. Bhatt, and M. Cohen Long-term use of ticagrelor in patients with prior myocardial infarction N Engl J Med 372 2015 1791 1800
5. G. Magnani, M.P. Bonaca, and E. Braunwald Efficacy and safety of vorapaxar as approved for clinical use in the United States J Am Heart Assoc 4 2015 e001505
6. J. Jamasbi, R.T.A. Megens, and M. Bianchini Differential inhibition of human atherosclerotic plaque-induced platelet activation by dimeric GPVI-Fc and anti-GPVI antibodies: functional and imaging studies J Am Coll Cardiol 65 2015 2404 2415
7. S.P. Jackson Arterial thrombosis - insidious, unpredictable and deadly Nat Med 17 2011 1423 1436
8. M. Moroi, S.M. Jung, K. Shinmyozu, Y. Tomiyama, A. Ordinas, and M. Diaz-Ricart Analysis of platelet adhesion to a collagen-coated surface under flow conditions: the involvement of glycoprotein VI in the platelet adhesion Blood 88 1996 2081 2092
9. S. Loyau, B. Dumont, and V. Ollivier Platelet glycoprotein VI dimerization, an active process inducing receptor competence, is an indicator of platelet reactivity Arterioscler Thromb Vasc Biol 32 2012 778 785
10. B. Bigalke, M. Haap, and K. Stellos Platelet glycoprotein VI (GPVI) for early identification of acute coronary syndrome in patients with chest pain Thromb Res 125 2010 e184 e189
11. M. Al-Tamimi, E.E. Gardiner, and J.Y. Thom Soluble glycoprotein VI is raised in the plasma of patients with acute ischemic stroke Stroke 42 2011 498 500
12. S. Dutting, and B. Nieswandt Better safe than sorry: glycoprotein VI dimerization as a novel checkpoint and early biomarker of platelet activation Arterioscler Thromb Vasc Biol 32 2012 552 553
13. J.F. Arthur, S. Dunkley, and R.K. Andrews Platelet glycoprotein VI-related clinical defects Br J Haematol 139 2007 363 372
14. M. Ungerer, Z. Li, and C. Baumgartner The GPVI-Fc fusion protein Revacept reduces thrombus formation and improves vascular dysfunction in atherosclerosis without any impact on bleeding times PLoS One 8 2013 e71193
15. M. Ungerer, K. Rosport, and A. Bultmann Novel antiplatelet drug Revacept (dimeric glycoprotein VI-Fc) specifically and efficiently inhibited collagen-induced platelet aggregation without affecting general hemostasis in humans Circulation 123 2011 1891 1899